Developer docs
API playgroundTry for free, no card

Search company profiles

Hemab

Full company profile

uuid0000c6k

Namestring
Hemab
Legal namestring
Hemab Therapeutics Holdings, Inc.
Websiteurl
hemab.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Hemab is a clinical-stage biotechnology company developing prophylactic antibody therapies for underserved inherited bleeding and thrombotic disorders, including Glanzmann thrombasthenia, Von Willebrand Disease, and congenital Factor VII deficiency. The company is dual-headquartered in Cambridge, Massachusetts (US principal office) and Frederiksberg/Copenhagen, Denmark (research and CMC hub), was founded in 2021, and completed its upsized initial public offering on the Nasdaq Global Select Market in May 2026 under the ticker COAG, raising approximately $301.5 million in gross proceeds (~$346.7 million with overallotment) at an $18.00 offer price and reaching a ~$1.4 billion first-day market capitalization.

Hemab's pipeline is anchored by two wholly owned clinical-stage product candidates built on a modality-agnostic antibody platform that engineers bispecific and monovalent antibodies to protect endogenous coagulation proteins, drive them to hemostatic levels, and direct them to activated platelets at sites of injury. The lead asset, sutacimig (HMB-001), is a bispecific antibody that accumulates and targets endogenous FVIIa to activated platelets, currently in a fully enrolled Phase 1/2 study (with long-term extension ongoing) for Glanzmann thrombasthenia and a Phase 2 study in congenital Factor VII deficiency, supported by positive complete Phase 2 data presented at ASH 2025 and a planned pivotal Phase 3 initiation in H2 2026. The second asset, HMB-002, is a monovalent antibody that elevates circulating VWF and FVIII levels for Von Willebrand Disease, currently in the Phase 1/2 VELORA Pioneer first-in-human study and supported by the VELORA Discover natural history screening study; clinical pharmacology was published in Blood Advances in January 2026.

Hemab is pre-revenue and has no commercially approved products or pricing; its near-term revenue mechanics are limited to investigational clinical-trial supply, Medical Affairs and Patient Advocacy engagement with hematologists, hemophilia treatment centers, and rare-bleeding-disorder communities, and capital markets activity. The company is funded through a $55M Series A (2021), $135M Series B (2023), $157M Series C (2025), and the 2026 Nasdaq IPO, with approximately $460M in pro-forma cash to fund its 'Hemab 2x3 by 2030' plan of two commercial launches and six major clinical milestones by 2030. Customer segments are defined by indication (Glanzmann, VWD, FVII deficiency patients) and by stakeholder type (HCPs/investigators, patient advocacy groups, and public-market investors), with no current product sales channel.

Short descriptiontext

Hemab is a clinical-stage biotech developing first-in-class subcutaneous prophylactic antibody therapies for underserved rare bleeding disorders — Glanzmann thrombasthenia, Von Willebrand Disease, and Factor VII deficiency — publicly listed on Nasdaq as COAG.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersFrederiksberg, Denmark
HQ citystring
Frederiksberg
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease biopharmaceuticals, bleeding disorder therapeutics, bispecific antibody development, monoclonal antibody therapies, subcutaneous prophylactic treatments
Industry4 codes
PRIMARYHLAIAHAB
Plasma-Derived Coagulation Factors (Hemophilia Therapies)
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAIAHAF
Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor)
SECONDARYHLAFAMAG
Transfusion Medicine & Immunohematology (Blood Bank)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Blood and Organ Banks621991
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease Biopharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue clinical development
TypeLicensing Royalties
Description

Hemab is a clinical-stage biotechnology company and is not yet generating product revenue. The company's lead assets (sutacimig for Glanzmann thrombasthenia/FVII deficiency, HMB-002 for VWD) are in Phase 1/2 to Phase 3 development. Following its May 2026 IPO, Hemab held approximately $460 million in pro-forma cash, intended to fund ongoing and upcoming registration studies rather than any current commercial sales.

in.investing.com
Marketing channels11 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Sutacimig
Description

Lead clinical-stage bispecific antibody product candidate (also designated HMB-001) being developed by Hemab for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency.

hemab.com
+1 more record
Core offering1 text field

Hemab is a clinical-stage biotechnology company developing first-in-class prophylactic antibody therapies for underserved inherited bleeding disorders. Its portfolio consists of two clinical-stage product candidates: Sutacimig (HMB-001), a bispecific antibody that targets endogenous FVIIa to activated platelets for subcutaneous prophylaxis in Glanzmann Thrombasthenia and Factor VII Deficiency, and HMB-002, a monovalent antibody that elevates endogenous VWF and FVIII levels for subcutaneous prophylaxis in Von Willebrand Disease. The company's modality-agnostic platform engineers antibodies that connect to the body's natural clotting proteins, stabilize them from premature breakdown, accumulate them to hemostatic levels, and direct them to sites of injury to drive localized coagulation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Positive complete Phase 2 data for sutacimig in Glanzmann thrombasthenia announced at ASH 2025, demonstrating significant reductions in bleeding events and safety, supporting advancement to a pivotal Phase 3 study
+3 more records
Product overview1 text field

Hemab Therapeutics operates a single, focused clinical-stage biotechnology pipeline rather than a multi-product platform. Its portfolio is anchored by two bispecific/monovalent antibody product candidates developed as subcutaneous prophylactic treatments for underserved inherited bleeding disorders. The lead asset, Sutacimig (HMB-001), is a bispecific antibody targeting FVIIa to activated platelets and is in Phase 1/2 (NCT06211634, fully enrolled with long-term extension ongoing) for Glanzmann Thrombasthenia, with a pivotal Phase 3 study anticipated in H2 2026 following positive complete Phase 2 data presented at ASH 2025; a separate Phase 2 study in Congenital Factor VII Deficiency (NCT07347249) is actively enrolling. The second asset, HMB-002, is a monovalent antibody that elevates circulating VWF and FVIII levels and is being developed in the actively enrolling Phase 1/2 VELORA Pioneer trial (NCT06754852) for Von Willebrand Disease, supported by the prospective natural history VELORA Discover screening study (NCT06610201). Hemab's broader R&D approach is modality-agnostic and targets Factor VII deficiency, Von Willebrand Disease, Glanzmann Thrombasthenia, and additional coagulation disorders, with all clinical and scientific communications centralized in the Empirium news and presentations hub.

Product and service2 records
1Sutacimig (HMB-001)
CategoryClinical-stage bispecific antibody therapeutic
Description

Sutacimig (HMB-001) is Hemab's lead clinical-stage product candidate, a first-in-class novel bispecific antibody that accumulates and targets endogenous FVIIa to activated platelets at sites of injury to enhance thrombin generation and fibrin formation. It is being developed as a subcutaneous prophylactic treatment for Glanzmann Thrombasthenia (Phase 1/2 NCT06211634, fully enrolled with long-term extension ongoing) and for Congenital Factor VII Deficiency (Phase 2 NCT07347249, actively enrolling single ascending dose cohorts).

2HMB-002
CategoryClinical-stage monovalent antibody therapeutic
Description

HMB-002 is Hemab's second clinical-stage product candidate, a first-in-class monovalent antibody designed to elevate circulating endogenous VWF and Factor VIII levels for subcutaneous prophylactic treatment of Von Willebrand Disease. It is currently being evaluated in the actively enrolling Phase 1/2 VELORA Pioneer trial (NCT06754852) and supported by the prospective VELORA Discover natural history screening study (NCT06610201).

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Rare-disease biotech pioneering RNAi therapeutics. Hemab's Board Chair John Maraganore was Alnylam's founding CEO for nearly 20 years; CEO Sorensen led fitusiran development at Alnylam; COO Murthy, VP Amin, Director Vaishnaw, and Head of Biometrics He all came from Alnylam, creating deep talent and approach overlap in rare-disease drug development.

TypeDirect peer
Description

Antibody platform biotech commercializing VYVGART for rare autoimmune diseases. Hemab's COO Anant Murthy was previously General Manager of EMEA at argenx and led the international launch of VYVGART, and the company shares a similar model of platform-driven antibody therapeutics for underserved indications with high unmet need.

TypeDirect peer
Description

Antibody platform company developing bispecific and next-generation antibody therapeutics. Multiple Hemab executives and directors (Bak-Thomsen, Jønsson, Goldenbæk, Poulsen) previously led antibody development, CMC, and analytics at Genmab, providing shared expertise in bispecific antibody design and regulatory-grade manufacturing.

TypeBroad incumbent
Description

Established rare-disease biotech with a commercial hemophilia franchise (e.g., Roctavian for hemophilia A gene therapy). BioMarin represents a larger, commercially active rare-disease peer with overlapping indication space (bleeding disorders) but a wider therapeutic portfolio.

TypeBroad incumbent
Description

Large pharmaceutical company with an established hemophilia and rare bleeding disorder franchise (Eloctate, Altuviiio, and Bioverativ legacy assets). Hemab's SVP CMC Cécile Bonvoisin previously led biologics manufacturing at Sanofi, and Sanofi operates as a broad incumbent in the same disease space Hemab targets.

TypeBroad incumbent
Description

Large pharmaceutical company that acquired Shire/Baxalta, inheriting a major hemophilia and bleeding-disorder franchise (Advate, Adynovate, Vonvendi). Hemab's VP Regulatory Erik Bjornson and Director Supply Chain Bernd Schaden both previously held senior roles across the Baxalta/Shire/Takeda hemophilia portfolio, and Takeda represents the dominant incumbent in the adjacent bleeding-disorder market.

TypeBroad incumbent
Description

Large pharmaceutical company with a global hemophilia franchise (NovoSeven, NovoEight, Refixia, Alhemo). Multiple Hemab scientific and clinical leaders (Østergaard, Laustsen, Mathy, Nagilla, Bak-Thomsen, Jensen, Jeppesen) and the Series A lead investor Novo Holdings connect Hemab's R&D approach to Novo Nordisk's hemophilia portfolio.

TypeBroad incumbent
Description

Large pharmaceutical company with hemophilia assets including the recently approved Beqvez gene therapy for hemophilia B (acquired via Spark Therapeutics) and broader rare-disease franchise. Pfizer represents a major incumbent competing in adjacent bleeding-disorder therapeutic modalities (gene therapy vs. Hemab's antibody approach).

TypeEmerging player
Description

Clinical-stage gene therapy company developing etranacogene dezaparvovec for hemophilia B. uniQure is comparable to Hemab as a focused, late-clinical-stage biotech addressing rare inherited bleeding disorders but pursues a gene-therapy modality rather than antibody-based prophylaxis.

TypeEmerging player
Description

Rare-disease biotech with TransCon technology platform and approved endocrine products. Multiple Hemab directors and VPs (Caroline Rasmussen, Anja Skands, Mette Ulbak) previously held senior nonclinical, drug-product, and regulatory roles at Ascendis, and the company represents a similarly sized rare-disease platform peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hemab

Rare Disease Biopharmaceuticalshemab.com

Hemab is a clinical-stage biotech developing first-in-class subcutaneous prophylactic antibody therapies for underserved rare bleeding disorders — Glanzmann thrombasthenia, Von Willebrand Disease, and Factor VII deficiency — publicly listed on Nasdaq as COAG.

What Hemab does

Hemab is a clinical-stage biotechnology company developing prophylactic antibody therapies for underserved inherited bleeding and thrombotic disorders, including Glanzmann thrombasthenia, Von Willebrand Disease, and congenital Factor VII deficiency. The company is dual-headquartered in Cambridge, Massachusetts (US principal office) and Frederiksberg/Copenhagen, Denmark (research and CMC hub), was founded in 2021, and completed its upsized initial public offering on the Nasdaq Global Select Market in May 2026 under the ticker COAG, raising approximately $301.5 million in gross proceeds (~$346.7 million with overallotment) at an $18.00 offer price and reaching a ~$1.4 billion first-day market capitalization.

Hemab's pipeline is anchored by two wholly owned clinical-stage product candidates built on a modality-agnostic antibody platform that engineers bispecific and monovalent antibodies to protect endogenous coagulation proteins, drive them to hemostatic levels, and direct them to activated platelets at sites of injury. The lead asset, sutacimig (HMB-001), is a bispecific antibody that accumulates and targets endogenous FVIIa to activated platelets, currently in a fully enrolled Phase 1/2 study (with long-term extension ongoing) for Glanzmann thrombasthenia and a Phase 2 study in congenital Factor VII deficiency, supported by positive complete Phase 2 data presented at ASH 2025 and a planned pivotal Phase 3 initiation in H2 2026. The second asset, HMB-002, is a monovalent antibody that elevates circulating VWF and FVIII levels for Von Willebrand Disease, currently in the Phase 1/2 VELORA Pioneer first-in-human study and supported by the VELORA Discover natural history screening study; clinical pharmacology was published in Blood Advances in January 2026.

Hemab is pre-revenue and has no commercially approved products or pricing; its near-term revenue mechanics are limited to investigational clinical-trial supply, Medical Affairs and Patient Advocacy engagement with hematologists, hemophilia treatment centers, and rare-bleeding-disorder communities, and capital markets activity. The company is funded through a $55M Series A (2021), $135M Series B (2023), $157M Series C (2025), and the 2026 Nasdaq IPO, with approximately $460M in pro-forma cash to fund its 'Hemab 2x3 by 2030' plan of two commercial launches and six major clinical milestones by 2030. Customer segments are defined by indication (Glanzmann, VWD, FVII deficiency patients) and by stakeholder type (HCPs/investigators, patient advocacy groups, and public-market investors), with no current product sales channel.

Hemab firmographics

Firmographics
Name
Hemab
Legal name
Hemab Therapeutics Holdings, Inc.
Website
https://hemab.com
Company type
Public
Founded year
2021
Operating status
Ipo
Headcount range
101–250 employees
Short description
Hemab is a clinical-stage biotech developing first-in-class subcutaneous prophylactic antibody therapies for underserved rare bleeding disorders — Glanzmann thrombasthenia, Von Willebrand Disease, and Factor VII deficiency — publicly listed on Nasdaq as COAG.
Ownership category
akta.pro rank

Hemab industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAHAB
Plasma-Derived Coagulation Factors (Hemophilia Therapies)
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAIAHAF
Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor)
SECONDARYHLAFAMAG
Transfusion Medicine & Immunohematology (Blood Bank)

Keywords

  • Rare disease biopharmaceuticals
  • Bleeding disorder therapeutics
  • Bispecific antibody development
  • Monoclonal antibody therapies
  • Subcutaneous prophylactic treatments

Where Hemab is headquartered

Location

Headquarters

HQ city
Frederiksberg
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

Hemab business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pre-revenue clinical development: Hemab is a clinical-stage biotechnology company and is not yet generating product revenue. The company's lead assets (sutacimig for Glanzmann thrombasthenia/FVII deficiency, HMB-002 for VWD) are in Phase 1/2 to Phase 3 development. Following its May 2026 IPO, Hemab held approximately $460 million in pro-forma cash, intended to fund ongoing and upcoming registration studies rather than any current commercial sales.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels11 records

Hemab product offering

Product offering

Core offering

Hemab is a clinical-stage biotechnology company developing first-in-class prophylactic antibody therapies for underserved inherited bleeding disorders. Its portfolio consists of two clinical-stage product candidates: Sutacimig (HMB-001), a bispecific antibody that targets endogenous FVIIa to activated platelets for subcutaneous prophylaxis in Glanzmann Thrombasthenia and Factor VII Deficiency, and HMB-002, a monovalent antibody that elevates endogenous VWF and FVIII levels for subcutaneous prophylaxis in Von Willebrand Disease. The company's modality-agnostic platform engineers antibodies that connect to the body's natural clotting proteins, stabilize them from premature breakdown, accumulate them to hemostatic levels, and direct them to sites of injury to drive localized coagulation.

Product overview

Hemab Therapeutics operates a single, focused clinical-stage biotechnology pipeline rather than a multi-product platform. Its portfolio is anchored by two bispecific/monovalent antibody product candidates developed as subcutaneous prophylactic treatments for underserved inherited bleeding disorders. The lead asset, Sutacimig (HMB-001), is a bispecific antibody targeting FVIIa to activated platelets and is in Phase 1/2 (NCT06211634, fully enrolled with long-term extension ongoing) for Glanzmann Thrombasthenia, with a pivotal Phase 3 study anticipated in H2 2026 following positive complete Phase 2 data presented at ASH 2025; a separate Phase 2 study in Congenital Factor VII Deficiency (NCT07347249) is actively enrolling. The second asset, HMB-002, is a monovalent antibody that elevates circulating VWF and FVIII levels and is being developed in the actively enrolling Phase 1/2 VELORA Pioneer trial (NCT06754852) for Von Willebrand Disease, supported by the prospective natural history VELORA Discover screening study (NCT06610201). Hemab's broader R&D approach is modality-agnostic and targets Factor VII deficiency, Von Willebrand Disease, Glanzmann Thrombasthenia, and additional coagulation disorders, with all clinical and scientific communications centralized in the Empirium news and presentations hub.

Differentiator

Problem solved

Functional benefit

Brands

  • Sutacimig: Lead clinical-stage bispecific antibody product candidate (also designated HMB-001) being developed by Hemab for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency.
  • Empirium

Products and services

  • Sutacimig (HMB-001) Sutacimig (HMB-001) is Hemab's lead clinical-stage product candidate, a first-in-class novel bispecific antibody that accumulates and targets endogenous FVIIa to activated platelets at sites of injury to enhance thrombin generation and fibrin formation. It is being developed as a subcutaneous prophylactic treatment for Glanzmann Thrombasthenia (Phase 1/2 NCT06211634, fully enrolled with long-term extension ongoing) and for Congenital Factor VII Deficiency (Phase 2 NCT07347249, actively enrolling single ascending dose cohorts).
  • HMB-002 HMB-002 is Hemab's second clinical-stage product candidate, a first-in-class monovalent antibody designed to elevate circulating endogenous VWF and Factor VIII levels for subcutaneous prophylactic treatment of Von Willebrand Disease. It is currently being evaluated in the actively enrolling Phase 1/2 VELORA Pioneer trial (NCT06754852) and supported by the prospective VELORA Discover natural history screening study (NCT06610201).

Quantifiable outcome

  • Positive complete Phase 2 data for sutacimig in Glanzmann thrombasthenia announced at ASH 2025, demonstrating significant reductions in bleeding events and safety, supporting advancement to a pivotal Phase 3 study
  • +3 more outcomes

Companies that use Hemab

Customer profile

Segments6 records

Ideal customer profiles4 records

Hemab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Hemab partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Hemab competitors and assessment

Company assessment

Direct peers

  • Alnylam Pharmaceuticals: Rare-disease biotech pioneering RNAi therapeutics. Hemab's Board Chair John Maraganore was Alnylam's founding CEO for nearly 20 years; CEO Sorensen led fitusiran development at Alnylam; COO Murthy, VP Amin, Director Vaishnaw, and Head of Biometrics He all came from Alnylam, creating deep talent and approach overlap in rare-disease drug development.
  • argenx: Antibody platform biotech commercializing VYVGART for rare autoimmune diseases. Hemab's COO Anant Murthy was previously General Manager of EMEA at argenx and led the international launch of VYVGART, and the company shares a similar model of platform-driven antibody therapeutics for underserved indications with high unmet need.
  • Genmab: Antibody platform company developing bispecific and next-generation antibody therapeutics. Multiple Hemab executives and directors (Bak-Thomsen, Jønsson, Goldenbæk, Poulsen) previously led antibody development, CMC, and analytics at Genmab, providing shared expertise in bispecific antibody design and regulatory-grade manufacturing.

Broad incumbents

  • BioMarin Pharmaceutical: Established rare-disease biotech with a commercial hemophilia franchise (e.g., Roctavian for hemophilia A gene therapy). BioMarin represents a larger, commercially active rare-disease peer with overlapping indication space (bleeding disorders) but a wider therapeutic portfolio.
  • Sanofi: Large pharmaceutical company with an established hemophilia and rare bleeding disorder franchise (Eloctate, Altuviiio, and Bioverativ legacy assets). Hemab's SVP CMC Cécile Bonvoisin previously led biologics manufacturing at Sanofi, and Sanofi operates as a broad incumbent in the same disease space Hemab targets.
  • Takeda Pharmaceutical: Large pharmaceutical company that acquired Shire/Baxalta, inheriting a major hemophilia and bleeding-disorder franchise (Advate, Adynovate, Vonvendi). Hemab's VP Regulatory Erik Bjornson and Director Supply Chain Bernd Schaden both previously held senior roles across the Baxalta/Shire/Takeda hemophilia portfolio, and Takeda represents the dominant incumbent in the adjacent bleeding-disorder market.
  • Novo Nordisk: Large pharmaceutical company with a global hemophilia franchise (NovoSeven, NovoEight, Refixia, Alhemo). Multiple Hemab scientific and clinical leaders (Østergaard, Laustsen, Mathy, Nagilla, Bak-Thomsen, Jensen, Jeppesen) and the Series A lead investor Novo Holdings connect Hemab's R&D approach to Novo Nordisk's hemophilia portfolio.
  • Pfizer: Large pharmaceutical company with hemophilia assets including the recently approved Beqvez gene therapy for hemophilia B (acquired via Spark Therapeutics) and broader rare-disease franchise. Pfizer represents a major incumbent competing in adjacent bleeding-disorder therapeutic modalities (gene therapy vs. Hemab's antibody approach).

Emerging players

  • uniQure: Clinical-stage gene therapy company developing etranacogene dezaparvovec for hemophilia B. uniQure is comparable to Hemab as a focused, late-clinical-stage biotech addressing rare inherited bleeding disorders but pursues a gene-therapy modality rather than antibody-based prophylaxis.
  • Ascendis Pharma: Rare-disease biotech with TransCon technology platform and approved endocrine products. Multiple Hemab directors and VPs (Caroline Rasmussen, Anja Skands, Mette Ulbak) previously held senior nonclinical, drug-product, and regulatory roles at Ascendis, and the company represents a similarly sized rare-disease platform peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Hemab social profiles

Digital presence

Hemab compliance and trust

Trust signal

Compliance3 records

Hemab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hemab leadership team

Management profile

Number of profiles

Profiles7 records

Hemab subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Hemab funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hemab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemab

What does Hemab do?

Hemab is a clinical-stage biotechnology company developing first-in-class prophylactic antibody therapies for underserved inherited bleeding disorders. Its portfolio consists of two clinical-stage product candidates: Sutacimig (HMB-001), a bispecific antibody that targets endogenous FVIIa to activated platelets for subcutaneous prophylaxis in Glanzmann Thrombasthenia and Factor VII Deficiency, and HMB-002, a monovalent antibody that elevates endogenous VWF and FVIII levels for subcutaneous prophylaxis in Von Willebrand Disease. The company's modality-agnostic platform engineers antibodies that connect to the body's natural clotting proteins, stabilize them from premature breakdown, accumulate them to hemostatic levels, and direct them to sites of injury to drive localized coagulation.

Is Hemab a public or private company?

Hemab is a public company. It is classified as public and is currently ipo.

When was Hemab founded?

Hemab was founded in 2021. It employs 101 to 250 people.

Where is Hemab based?

Hemab is headquartered in Frederiksberg, Denmark, in the Europe region.

How does Hemab make money?

One revenue line is on record: pre-revenue clinical development.

Who are Hemab's main competitors?

Direct peers on record are Alnylam Pharmaceuticals, argenx and Genmab. Broad incumbents are BioMarin Pharmaceutical, Sanofi, Takeda Pharmaceutical, Novo Nordisk and Pfizer. Emerging players are uniQure and Ascendis Pharma.

Does Hemab have an API?

No public API is recorded for Hemab.

What industry is Hemab in?

Hemab's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAHAB, Plasma-Derived Coagulation Factors (Hemophilia Therapies), with a secondary code of HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate소피노바, 7억2500만 유로 바이오 투자펀드 조성…유럽 신약개발 기업 성장 지원 : 네이트 뉴스Sofinnova Partners raised €725 million for its second crossover fund, the largest of its series, to support European biotech firms. The fund will invest in about 15 companies, including Hemab Therapeutics and CellCentric, and includes participation from the European Technology Champions Initiative.MarketScreenerSofinnova closes EUR725 million fund to back European biotech expansionSofinnova Partners closed a EUR725 million crossover fund, above its target, to back European biotechs seeking global competition. The fund, Crossover II, will invest in about 15 companies, including Hemab Therapeutics and CellCentric, and aims to build companies for longevity without M&A.BioPharma DiveOne of Europe’s leading VCs banks a €725M ‘crossover’ fundSofinnova Partners raised €725M ($815M) for its second crossover fund, targeting companies near commercialization. The fund will invest in about 15 drugmakers and medical device developers, mostly in Europe. The firm's largest fund has already funded companies like CellCentric and Hemab Therapeutics.YahooOne of Europe’s leading VCs banks a €725M ‘crossover’ fundSofinnova Partners raised €725 million ($815 million) for its second crossover fund, targeting companies near commercialization. The fund will invest in about 15 drugmakers and medical device developers, mostly in Europe, and has already funded companies like CellCentric and Hemab Therapeutics.BNNHot Picks: Three U.S. biotech stocks to watchWedbush analyst David Nierengarten discussed Scholar Rock, Disc Medicine, and Hemab Therapeutics, focusing on rare disease treatments. Scholar Rock's Isembyld launch faces infusion scheduling delays, Disc Medicine's bitopertin expects FDA decision by mid-2027, and Hemab's Phase 3 SOLARA trial for Glanzmann thrombasthenia is underway.Business & FinancialHemab Therapeutics To Participate In Upcoming Investor ConferencesHemab Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference on November 17, 2026, and the 9th Annual Evercore Healthcare Conference on December 1, 2026. Both events will feature a fireside chat, with a live webcast available for replay on the company's website.Stock TitanHemab Therapeutics to Join Two Investor ConferencesHemab Therapeutics announced its management team will participate in two investor conferences: the Jefferies Global Healthcare Conference on November 17, 2026, and the Evercore Healthcare Conference on December 1, 2026. The company also stated that live webcasts of the presentations will be available for replay on its website.MarketScreenerHemab Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Hemab Therapeutics reported a Q3 net loss of $27.3 million and a nine-month net loss of $74.14 million, both worse than the prior year. Basic and diluted loss per share from continuing operations were $0.58 and $2.84, respectively, compared to $18.04 and $47.12 a year ago.ChartmillHemab Therapeutics Holdings (NASDAQ:COAG) Posts Wider Q3 Loss as Pipeline Catalysts Lift StockHemab Therapeutics reported a Q3 net loss of $27.3 million, wider than consensus, with no revenue. The company's stock rose pre-market, driven by pipeline catalysts including the initiation of a Phase 3 trial for sutacimig in Glanzmann thrombasthenia and positive Factor VII deficiency data. Management cited a $430.2 million cash runway into 2029.Quiver QuantitativeHEMAB THERAPEUTICS ($COAG) Releases Q3 2026 Earnings | COAG Stock NewsHEMAB Therapeutics reported Q3 2026 earnings of -$0.58 per share, missing estimates of -$0.53, with revenue of $0. Insiders made five purchases in the past six months, and five analysts have set a median price target of $40.0.